With new federal funding in hand, Tal Medical plans to launch a clinical trial of its Low Field Magnetic Stimulation technology for treating depression.
Tal Medical said it won funding from the National Institute of Mental Health, allowing the company to conduct a clinical trial of its Low Field Magnetic Stimulation technology in treating depression.
The LFMS technology is a non-invasive neuromodulation system that delivers magnetic stimulation to the brain through an external electromagnetic coil.
The NIMH awarded the funding through its Rapidly Acting Treatments for Treatment Resistant Depression program, a new initiative dedicated to identifying and testing "promising anti-depressant interventions," according to a press release.
The federal funding brings Tal Medical’s take to about $6 million in support of its trial, according to a spokesperson for PureTech Ventures, a life sciences venture capital group that helped launch Tal Medical in 2010.
The LMFS trial is funded on a contract between NIHMH and Massachusetts General Hospital, according to PureTech. The trial is a 90-patient, 6-site, sham-controlled study in patients who have responded negatively to 1-3 antidepressant treatments. In addition to MGH, the trial will also be run by Yale, Mount Sinai and Emory, among other leading hospitals.
"There is a well-documented lack of innovation in the field of antidepressant drug development and LFMS has the potential to break this paradigm and offer patients a clinical profile completely different from that of current therapies. The sham-controlled data with LFMS indicate an antidepressant response within minutes of patients receiving a single 20 minute LFMS treatment," Tal Medical co-founder and chairman Dr. Steve Paul said in prepared remarks.
A California appeals court upholds a $5 million judgment against C.R. Bard and the surgeon involved...
Here's a look at some of the top Wall Street stories for medical device companies this week: InVivo...
Hologic fires its chief administrative officer, Mark Casey, effective Dec. 19.
IlluminOss Medical says the FDA cleared a clinical trial of its photodynamic bone stabilization...